NMT2

Summary

NMT2 (N-myristoyltransferase 2, HGNC:7858) is a protein-coding gene on chromosome 10p13, encoding Glycylpeptide N-tetradecanoyltransferase 2 (O60551). Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins.

This gene encodes one of two N-myristoyltransferase proteins. N-terminal myristoylation is a lipid modification that is involved in regulating the function and localization of signaling proteins. The encoded protein catalyzes the addition of a myristoyl group to the N-terminal glycine residue of many signaling proteins, including the human immunodeficiency virus type 1 (HIV-1) proteins, Gag and Nef. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9397 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 78 total
• Druggable target: yes
• MANE Select transcript: NM_004808

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7858
Approved symbol	NMT2
Name	N-myristoyltransferase 2
Location	10p13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000152465
Ensembl biotype	protein_coding
OMIM	603801
Entrez	9397

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000378150, ENST00000378165, ENST00000466201, ENST00000478580, ENST00000486786, ENST00000903368, ENST00000903369, ENST00000903370, ENST00000903371, ENST00000903372, ENST00000954252

RefSeq mRNA: 2 — MANE Select: NM_004808 NM_001308295, NM_004808

CCDS: CCDS7109, CCDS76284

Canonical transcript exons

ENST00000378165 — 12 exons

Exon	Start	End
ENSE00001614281	15119343	15119513
ENSE00001733830	15128350	15128458
ENSE00001794131	15130142	15130312
ENSE00001812561	15105770	15109215
ENSE00001901915	15168503	15168693
ENSE00003466409	15141422	15141557
ENSE00003514248	15135274	15135418
ENSE00003520733	15133053	15133144
ENSE00003536584	15132817	15132933
ENSE00003552637	15112796	15112963
ENSE00003600019	15109702	15109839
ENSE00003674605	15133245	15133363

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 94.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.7132 / max 246.5429, expressed in 1789 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108415	11.1370	1694
108414	8.8063	1701
108416	0.7278	447
108411	0.0421	20

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	94.61	gold quality
cortical plate	UBERON:0005343	92.19	gold quality
ventricular zone	UBERON:0003053	90.65	gold quality
adipose tissue	UBERON:0001013	90.36	gold quality
subcutaneous adipose tissue	UBERON:0002190	89.80	gold quality
connective tissue	UBERON:0002384	89.34	gold quality
cerebellar hemisphere	UBERON:0002245	89.15	gold quality
cerebellar cortex	UBERON:0002129	89.08	gold quality
ganglionic eminence	UBERON:0004023	88.77	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.53	gold quality
adipose tissue of abdominal region	UBERON:0007808	88.14	gold quality
cerebellum	UBERON:0002037	87.96	gold quality
tibia	UBERON:0000979	87.94	gold quality
omental fat pad	UBERON:0010414	87.87	gold quality
peritoneum	UBERON:0002358	87.82	gold quality
lateral nuclear group of thalamus	UBERON:0002736	87.41	gold quality
calcaneal tendon	UBERON:0003701	86.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.95	gold quality
primary visual cortex	UBERON:0002436	85.81	gold quality
right lobe of liver	UBERON:0001114	85.79	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.39	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.25	gold quality
right frontal lobe	UBERON:0002810	85.02	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.00	gold quality
adrenal tissue	UBERON:0018303	84.95	gold quality
prefrontal cortex	UBERON:0000451	84.74	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	84.66	gold quality
mucosa of transverse colon	UBERON:0004991	84.21	gold quality
left ovary	UBERON:0002119	84.14	gold quality
right ovary	UBERON:0002118	83.98	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	13.16
E-ANND-3	yes	8.29
E-CURD-112	yes	6.35
E-MTAB-9801	yes	6.09
E-MTAB-4850	no	385.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

161 targeting NMT2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197

Literature-anchored findings (GeneRIF, showing 8)

• induction of NMT2 may play a central role in dioxin carcinogenicity. (PMID:11731439)
• NMT1 and NMT2 have only partially overlapping functions; NMT1 is critical for tumor cell proliferation (PMID:16123142)
• Involved in progression and regulation of telomerase (PMID:16364039)
• Protein-protein interaction of NMTs revealed that m-calpain interacts with NMT1 while caspase-3 interacts with NMT2. (PMID:16530191)
• Disruption of the gene for NMT2 by a t(8;10) translocation in a male with hypogonadism. (PMID:17568424)
• Nef is preferentially myristoylated by NMT2, suggesting that selective inhibition of NMT2 may provide a novel means of blocking HIV virulence. (PMID:18089753)
• ligand binding properties of the NMT/ACBD6 complex can explain how the NMT reaction can proceed in the presence of the very abundant competitive substrate, C(16)-CoA. (PMID:26621918)
• N-mytistoyltransferase 1 and 2 are potential tumor suppressors and novel targets of miR-182 in human non-small cell lung carcinomas. (PMID:35930829)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nmt2	ENSDARG00000021808
mus_musculus	Nmt2	ENSMUSG00000026643
rattus_norvegicus	Nmt2	ENSRNOG00000026248
drosophila_melanogaster	Nmt	FBGN0020392
caenorhabditis_elegans		WBGENE00020549

Paralogs (1): NMT1 (ENSG00000136448)

Protein

Protein identifiers

Glycylpeptide N-tetradecanoyltransferase 2 — O60551 (reviewed: O60551)

Alternative names: Myristoyl-CoA:protein N-myristoyltransferase 2, Peptide N-myristoyltransferase 2, Protein-lysine myristoyltransferase NMT2, Type II N-myristoyltransferase

All UniProt accessions (2): O60551, Q5VUC6

UniProt curated annotations — full annotation on UniProt →

Function. Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins. Also able to mediate N-terminal lysine myristoylation of proteins: catalyzes myristoylation of ARF6 on both ‘Gly-2’ and ‘Lys-3’. Lysine myristoylation is required to maintain ARF6 on membranes during the GTPase cycle.

Subcellular location. Cytoplasm. Membrane.

Similarity. Belongs to the NMT family.

RefSeq proteins (2): NP_001295224, NP_004799* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000903	NMT	Family
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR022676	NMT_N	Domain
IPR022677	NMT_C	Domain
IPR022678	NMT_CS	Conserved_site

Pfam: PF01233, PF02799

Enzyme classification (BRENDA):

• EC 2.3.1.97 — glycylpeptide N-tetradecanoyltransferase (BRENDA: 25 organisms, 184 substrates, 380 inhibitors, 83 Km, 22 kcat entries)

Substrate kinetics (BRENDA)

36 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
MYRISTOYL-COA	—	23
CAMP-DEPENDENT PROTEIN KINASE-DERIVED PEPTIDE	0.1–0.2	5
GLY-ASN-ALA-ALA-SER-ALA-ARG-ARG	0.0001–0.006	5
GLY-ASN-ALA-ALA-ALA-ALA-ARG-ARG	0.016–0.6	4
P60SRC-DERIVED PEPTIDE	0.016–0.06	4
CAP5.5 PEPTIDE	0.012–0.25	2
HIV-1 NEGATIVE REGULATORY FACTOR	0.0144–0.0257	2
HIV1 GAG PROTEIN N-TERMINAL PEPTIDE	0.196–0.33	2
HIV1 NEF PROTEIN N-TERMINAL PEPTIDE	0.0015–0.011	2
PEPTIDE HS PP60SRC(2-9)	0.0028	2
11-(ETHYLTHIO)-UNDECANOYL-COA	0.0007	1
ARABIDOPSIS THALIANA PROTEIN CDPK6-DERIVED PEPTI	0.0205	1
ARF PEPTIDE	0.0175	1
CAP5.5	0.022	1
GCGGSKVK	0.0113	1

Catalyzed reactions (Rhea), 2 shown:

• N-terminal glycyl-[protein] + tetradecanoyl-CoA = N-tetradecanoylglycyl-[protein] + CoA + H(+) (RHEA:15521)
• N-terminal glycyl-L-lysyl-[protein] + tetradecanoyl-CoA = N-terminal glycyl-(N(6)-tetradecanoyl)-L-lysyl-[protein] + CoA + H(+) (RHEA:70671)

UniProt features (54 total): strand 20, helix 15, binding site 8, turn 4, compositionally biased region 3, chain 1, region of interest 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6PAU	X-RAY DIFFRACTION	1.93
4C2X	X-RAY DIFFRACTION	2.33
9NDP	ELECTRON MICROSCOPY	2.82

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60551-F1	81.81	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 260; 261; 262; 117; 122; 250; 252; 258

Post-translational modifications (1): 38

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-174490	Membrane binding and targetting of GAG proteins
R-HSA-203615	eNOS activation
R-HSA-2514859	Inactivation, recovery and regulation of the phototransduction cascade

MSigDB gene sets: 232 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, HORIUCHI_WTAP_TARGETS_DN, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_BRCA1, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN, GOBP_PHOTOTRANSDUCTION, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, CHANG_IMMORTALIZED_BY_HPV31_DN, chr10p13, REACTOME_HIV_INFECTION, GOBP_PHOTOTRANSDUCTION_VISIBLE_LIGHT, GOBP_LIPOPROTEIN_BIOSYNTHETIC_PROCESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN

GO Biological Process (5): N-terminal peptidyl-glycine N-myristoylation (GO:0018008), regulation of opsin-mediated signaling pathway (GO:0022400), protein localization to membrane (GO:0072657), intracellular transport of virus (GO:0075733), N-terminal protein myristoylation (GO:0006499)

GO Molecular Function (5): glycylpeptide N-tetradecanoyltransferase activity (GO:0004379), peptidyl-lysine N6-myristoyltransferase activity (GO:0018030), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (6): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), cytosol (GO:0005829), plasma membrane (GO:0005886), host cell (GO:0043657), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Synthesis And Processing Of GAG, GAGPOL Polyproteins	1
Metabolism of nitric oxide: NOS3 activation and regulation	1
The phototransduction cascade	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
myristoyltransferase activity	2
cytoplasm	2
N-terminal protein myristoylation	1
peptidyl-glycine modification	1
regulation of G protein-coupled receptor signaling pathway	1
G protein-coupled opsin signaling pathway	1
regulation of response to external stimulus	1
intracellular protein localization	1
localization within membrane	1
viral life cycle	1
host cell	1
biological process involved in symbiotic interaction	1
transport of virus	1
N-terminal protein lipidation	1
protein myristoylation	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
transferase activity	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
host cellular component	1

Protein interactions and networks

STRING

862 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NMT2	ACBD6	Q9BR61	768
NMT2	GNAO1	P09471	589
NMT2	MED6	O75586	546
NMT2	CCDC106	Q9BWC9	516
NMT2	CASP3	P42574	457
NMT2	SAMD15	Q9P1V8	455
NMT2	METAP2	P50579	431
NMT2	NVL	O15381	423
NMT2	AKAP13	Q12802	422
NMT2	METAP1	P53582	419
NMT2	PPM1A	P35813	419
NMT2	NDN	Q99608	418
NMT2	MST1R	Q04912	408
NMT2	DBI	P07108	408
NMT2	TP53	P04637	402

IntAct

132 interactions, top by confidence:

A	B	Type	Score
ACBD6	NMT2	psi-mi:“MI:0914”(association)	0.870
ACBD6	NMT2	psi-mi:“MI:0915”(physical association)	0.870
NMT2	ACBD6	psi-mi:“MI:0915”(physical association)	0.870
NMT2	ACBD6	psi-mi:“MI:0407”(direct interaction)	0.870
ACBD6	NMT2	psi-mi:“MI:0214”(myristoylation reaction)	0.870
ACBD6	NMT2	psi-mi:“MI:0211”(lipid addition)	0.870
PRPS1	PRPSAP2	psi-mi:“MI:0914”(association)	0.840
PRPS2	PRPSAP2	psi-mi:“MI:0914”(association)	0.670
CSNK2B	NMT2	psi-mi:“MI:0914”(association)	0.660
NMT2	CSNK2B	psi-mi:“MI:0915”(physical association)	0.660
LRATD2	NMT2	psi-mi:“MI:0915”(physical association)	0.640
PRPS1	NMT2	psi-mi:“MI:0914”(association)	0.640
LRATD2	NMT2	psi-mi:“MI:0914”(association)	0.640
	NMT2	psi-mi:“MI:0407”(direct interaction)	0.620
	NMT2	psi-mi:“MI:0214”(myristoylation reaction)	0.620
	NMT2	psi-mi:“MI:0211”(lipid addition)	0.620
CASP3	NMT2	psi-mi:“MI:0570”(protein cleavage)	0.610
NMT2	CASP3	psi-mi:“MI:0915”(physical association)	0.610
	NMT2	psi-mi:“MI:0214”(myristoylation reaction)	0.560
	NMT2	psi-mi:“MI:0407”(direct interaction)	0.560

BioGRID (100): TP53 (Affinity Capture-Western), BCL2 (Affinity Capture-Western), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS), NMT2 (Affinity Capture-MS)

ESM2 similar proteins: A2VE39, D2HRF1, O02697, O60551, P26446, P42338, P48736, P60670, Q1MTD3, Q28E61, Q28FT4, Q295E6, Q2T9V5, Q4KLT3, Q4R6F3, Q5R981, Q5U2U7, Q5U2Z5, Q5XI55, Q5ZJM3, Q69ZX6, Q6GQ76, Q6P3K3, Q6PCN7, Q803R5, Q80VJ4, Q8BTI9, Q8BYH3, Q8CE96, Q8K1Q0, Q8K224, Q8K4M9, Q8N1G2, Q8R3N6, Q8TAT6, Q91XL9, Q95216, Q96IV0, Q9BXW6, Q9D0L8

Diamond homologs: A7YT82, O43010, O60551, O61613, O70310, O70311, O74234, P0CP20, P0CP21, P14743, P30418, P30419, P31717, P34763, P34809, P46548, Q4I061, Q4PB56, Q553B6, Q5RAF3, Q6BJF4, Q6C7G2, Q6CMK4, Q75EK2, Q7S3C8, Q8ILW6, Q8K1Q0, Q8TFN1, Q94L32, Q9LTR9, Q9N181, Q9U419, Q9UVX3, Q9EMI7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
ESR-mediated signaling	5	12.3×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
double-strand break repair	5	13.5×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2429 predictions. Top by Δscore:

Variant	Effect	Δscore
10:15103288:ATTTT:A	acceptor_gain	1.0000
10:15103292:T:A	acceptor_gain	1.0000
10:15109697:CTTA:C	donor_loss	1.0000
10:15109698:TTA:T	donor_loss	1.0000
10:15109700:A:AC	donor_gain	1.0000
10:15109701:C:CC	donor_gain	1.0000
10:15109701:C:CT	donor_loss	1.0000
10:15109836:CTTT:C	acceptor_gain	1.0000
10:15109838:TT:T	acceptor_gain	1.0000
10:15109840:C:CC	acceptor_gain	1.0000
10:15109840:C:T	acceptor_loss	1.0000
10:15109844:C:CT	acceptor_gain	1.0000
10:15109844:C:T	acceptor_gain	1.0000
10:15109845:A:T	acceptor_gain	1.0000
10:15109846:A:AC	acceptor_gain	1.0000
10:15109846:A:C	acceptor_gain	1.0000
10:15109847:T:C	acceptor_gain	1.0000
10:15109847:T:TC	acceptor_gain	1.0000
10:15109848:T:C	acceptor_gain	1.0000
10:15109848:T:TC	acceptor_gain	1.0000
10:15112645:T:C	donor_gain	1.0000
10:15112790:GCTTA:G	donor_loss	1.0000
10:15112791:CTTAC:C	donor_loss	1.0000
10:15112792:TTA:T	donor_loss	1.0000
10:15112793:TACCG:T	donor_loss	1.0000
10:15112794:A:AC	donor_gain	1.0000
10:15112794:A:T	donor_loss	1.0000
10:15112794:AC:A	donor_gain	1.0000
10:15112795:C:CA	donor_gain	1.0000
10:15112795:CC:C	donor_gain	1.0000

AlphaMissense

3289 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:15109731:A:G	W483R	1.000
10:15109731:A:T	W483R	1.000
10:15109751:A:C	L476W	1.000
10:15109751:A:G	L476S	1.000
10:15109757:C:T	G474D	1.000
10:15109763:C:T	G472E	1.000
10:15109764:C:G	G472R	1.000
10:15109764:C:T	G472R	1.000
10:15109771:A:C	F469L	1.000
10:15109771:A:T	F469L	1.000
10:15109772:A:G	F469S	1.000
10:15109773:A:G	F469L	1.000
10:15109773:A:T	F469I	1.000
10:15109818:C:G	A454P	1.000
10:15109819:A:C	N453K	1.000
10:15109819:A:T	N453K	1.000
10:15109821:T:C	N453D	1.000
10:15109826:A:T	V451E	1.000
10:15112803:G:T	A444D	1.000
10:15112870:A:G	Y422H	1.000
10:15112872:G:T	A421D	1.000
10:15112875:G:T	A420D	1.000
10:15112931:G:C	S401R	1.000
10:15112931:G:T	S401R	1.000
10:15112933:T:G	S401R	1.000
10:15128410:A:C	F313L	1.000
10:15128410:A:T	F313L	1.000
10:15128411:A:C	F313C	1.000
10:15128411:A:G	F313S	1.000
10:15128412:A:C	F313V	1.000

dbSNP variants (sampled 300 via entrez): RS1000071187 (10:15122036 T>A,C), RS1000072753 (10:15149051 C>T), RS1000099667 (10:15106909 C>T), RS1000120230 (10:15161800 T>A,C), RS1000122961 (10:15159935 C>T), RS1000149096 (10:15114613 T>C,G), RS1000203375 (10:15114915 T>A,C), RS1000231531 (10:15121141 T>A), RS1000250097 (10:15142743 G>C), RS1000324792 (10:15144547 T>A,C), RS1000327034 (10:15116225 G>A), RS1000373473 (10:15144254 C>A,T), RS1000406412 (10:15126814 G>A), RS1000482430 (10:15113210 C>G), RS1000619707 (10:15138427 C>T)

Disease associations

OMIM: gene MIM:603801 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002595_16	Clozapine-induced agranulocytosis	5.000000e-06
GCST008359_6	Response to cognitive-behavioural therapy in anxiety disorder	4.000000e-06
GCST008394_5	Mild to moderate chronic kidney disease	4.000000e-08
GCST009892_1	Osteoporosis-related phenotypes (MTAG)	1.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007820	cognitive behavioural therapy
EFO:0007702	hip bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2096973 (PROTEIN FAMILY), CHEMBL2849 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — N-myristoyltransferases

ChEMBL bioactivities

118 potent at pChembl≥5 of 176 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.41	IC50	0.39	nM	CHEMBL170807
9.40	IC50	0.4	nM	CHEMBL173370
9.24	IC50	0.58	nM	CHEMBL171506
9.15	IC50	0.71	nM	CHEMBL170524
8.89	IC50	1.3	nM	CHEMBL422896
8.89	IC50	1.3	nM	CHEMBL355497
8.70	IC50	2	nM	CHEMBL422746
8.52	IC50	3	nM	CHEMBL1230468
8.46	IC50	3.5	nM	CHEMBL355250
8.43	IC50	3.7	nM	CHEMBL158172
8.43	IC50	3.7	nM	CHEMBL155301
8.43	IC50	3.7	nM	CHEMBL347895
8.43	IC50	3.7	nM	CHEMBL155469
8.43	IC50	3.7	nM	CHEMBL345893
8.43	IC50	3.7	nM	CHEMBL347048
8.28	IC50	5.2	nM	CHEMBL158172
8.25	IC50	5.6	nM	CHEMBL347048
8.24	IC50	5.7	nM	CHEMBL347048
8.12	IC50	7.5	nM	CHEMBL345893
8.08	IC50	8.3	nM	CHEMBL347895
8.03	IC50	9.4	nM	CHEMBL155469
7.77	IC50	17	nM	CHEMBL351774
7.70	IC50	20	nM	CHEMBL291791
7.55	IC50	28	nM	CHEMBL158185
7.40	IC50	40	nM	CHEMBL188653
7.38	IC50	42	nM	CHEMBL59835
7.37	IC50	43	nM	CHEMBL353541
7.33	IC50	47	nM	CHEMBL172471
7.25	IC50	56	nM	SC-58272
7.22	Ki	60	nM	CHEMBL33664
7.21	IC50	62	nM	CHEMBL353249
7.16	Ki	70	nM	CHEMBL33289
7.14	IC50	73	nM	CHEMBL433886
7.14	IC50	72	nM	CHEMBL346363
7.09	IC50	81	nM	CHEMBL89727
7.04	IC50	91	nM	CHEMBL173962
7.00	IC50	100	nM	CHEMBL301315
7.00	Ki	100	nM	CHEMBL4172452
7.00	Ki	100	nM	CHEMBL4176755
6.96	IC50	110	nM	CHEMBL33289
6.96	IC50	110	nM	CHEMBL154079
6.89	IC50	130	nM	CHEMBL291811
6.83	IC50	147	nM	CHEMBL88093
6.70	IC50	200	nM	CHEMBL89452
6.64	IC50	230	nM	CHEMBL34801
6.58	IC50	260	nM	CHEMBL279641
6.52	IC50	300	nM	CHEMBL54883
6.51	IC50	310	nM	CHEMBL62081
6.51	IC50	310	nM	CHEMBL294596
6.47	IC50	340	nM	CHEMBL341147

PubChem BioAssay actives

109 with measured affinity, of 256 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5-methyl-2-pyridinyl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143932: In vitro inhibitory activity against candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0004	uM
(1-methylbenzimidazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0004	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(1-prop-2-enylbenzimidazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0006	uM
(4,5-dimethyl-1,3-thiazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0007	uM
(1-methylimidazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0013	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(1-propan-2-ylbenzimidazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0013	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(4-methyl-1,3-thiazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0020	uM
2,6-dichloro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171508: Inhibition of human N-myristoyltransferase 2 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0030	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-pyridin-2-ylmethanone	143923: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0035	uM
3-[[2-[(2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143884: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration	ic50	0.0037	uM
3-[[2-[(4-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[2-[(2,3-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[2-[(2,4-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143886: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM); 3.7-9.4 nM	ic50	0.0037	uM
4-[[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methoxy]benzonitrile	143889: Inhibitory activity against Candida albicans N-Myristoyltransferase (Nmt)	ic50	0.0037	uM
2-[[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methoxy]benzonitrile	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.0170	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[(2R)-2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]propanoyl]amino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.0200	uM
3-[[2-[(4-bromo-2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.0280	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]propanoylamino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.0400	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]butanoylamino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.0420	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-[3-(trifluoromethyl)-2-pyridinyl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0430	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-pyridin-2-ylmethanol	143935: Inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0470	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]acetyl]amino]propanoyl]amino]hexanamide	143934: Inhibitory activity against Candida albicans N-Myristoyltransferase (NMT).	ic50	0.0560	uM
(2S)-6-amino-2-[[(2S)-2-[[2-[4-(6-aminohexyl)phenyl]acetyl]amino]-3-hydroxypropanoyl]amino]-N-(2-cyclohexylethyl)hexanamide	143942: The binding affinity was evaluated towards N-myristoyltransferase (NMT) in the presence of the peptide substrate GNAASARR-NH2	ki	0.0600	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-pyridin-3-ylmethanone	143935: Inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0620	uM
11-amino-N-[(2S)-1-[[(2S)-6-amino-1-(2-cyclohexylethylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]undecanamide	143942: The binding affinity was evaluated towards N-myristoyltransferase (NMT) in the presence of the peptide substrate GNAASARR-NH2	ki	0.0700	uM
3-[[3-methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.0720	uM
3-[[2-[(4-chlorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.0730	uM
(2R)-2-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-methoxy-3-oxopropanoic acid	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.0810	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(1,3-thiazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0910	uM
ethyl 4-ethylsulfanyl-6-[(6-piperazin-1-yl-3-pyridinyl)methoxy]quinoline-3-carboxylate	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.1000	uM
ethyl 6-[[6-(3-aminopropylamino)-3-pyridinyl]methoxy]-4-ethylsulfanylquinoline-3-carboxylate	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.1000	uM
ethyl 3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-carboxylate	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.1000	uM
3-[[2-[(3-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.1100	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]pentanoylamino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.1300	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-2-[[2-[4-[4-(2-ethylimidazol-1-yl)butyl]phenyl]acetyl]amino]-3-hydroxypropanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.1470	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[2-[4-[4-(2-propan-2-ylimidazol-1-yl)butyl]phenyl]acetyl]amino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.2000	uM
11-amino-N-[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]undecanamide	144065: Inhibitory activity against human N-Myristoyltransferase (NMT).	ic50	0.2300	uM
11-amino-N-[(2S)-1-[[(2S)-6-amino-1-(2-cyclooctylethylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]undecanamide	143934: Inhibitory activity against Candida albicans N-Myristoyltransferase (NMT).	ic50	0.3000	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[2-[4-(4-imidazol-1-ylbutyl)phenyl]acetyl]amino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.3100	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]propanoyl]amino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.3100	uM
ethyl 4-ethylsulfanyl-6-[[6-[[(3R)-pyrrolidin-3-yl]amino]-3-pyridinyl]methoxy]quinoline-3-carboxylate	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.3700	uM
(2S)-2-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]propanoylamino]propanoyl]amino]hexanoyl]amino]-3-cyclohexylpropanoic acid	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.3800	uM
ethyl 6-[[6-(2-aminoethylamino)-3-pyridinyl]methoxy]-4-ethylsulfanylquinoline-3-carboxylate	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.4100	uM
11-amino-N-[(2S)-1-[[(2S)-6-amino-1-(3-methylbutylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]undecanamide	144064: Inhibition of human N-myristoyltransferase (NMT)	ic50	0.4200	uM
(4-ethylsulfanyl-6-phenylmethoxyquinolin-3-yl)-morpholin-4-ylmethanone	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.5900	uM
3-[[3-methyl-2-(phenylsulfanylmethyl)-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.6200	uM
ethyl 4-ethylsulfanyl-6-[[6-(piperidin-4-ylamino)-3-pyridinyl]methoxy]quinoline-3-carboxylate	1506566: Inhibition of N-terminal deletion human NMT2 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.6900	uM
N-[(2S)-1-[[(2S)-6-amino-1-(2-cyclohexylethylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-7-[4-(aminomethyl)phenyl]hept-6-ynamide	144064: Inhibition of human N-myristoyltransferase (NMT)	ic50	0.7600	uM
(2S)-6-amino-2-[[(2S)-2-[2-[4-(6-aminohexyl)phenyl]propanoylamino]-3-hydroxypropanoyl]amino]-N-(2-cyclohexylethyl)hexanamide	144064: Inhibition of human N-myristoyltransferase (NMT)	ic50	0.7900	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Arsenic	decreases expression, increases abundance, affects methylation, affects cotreatment	2
Quercetin	decreases expression, decreases phosphorylation	2
Silicon Dioxide	increases expression	2
Valproic Acid	decreases methylation, increases expression	2
Cyclosporine	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
trichostatin A	increases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
potassium chromate(VI)	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
bisphenol B	increases expression	1
(+)-JQ1 compound	increases expression	1
Arsenic Trioxide	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Doxorubicin	affects response to substance	1
Etoposide	affects response to substance	1

ChEMBL screening assays

48 unique, capped per target: 48 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL744115	Binding	Tested for Inhibitory concentration against human N-myristoyltransferase (NMT) in radiochemical HPLC end point assay with peptide GNAASARR-NH2 and [3H]myristoyl-CoA radioligand at 1 uM	Replacements for lysine in l-seryl-l-lysyl dipeptide amide inhibitors of candida albicans myristoyl-CoA:protein N-myristoyltransferase — Bioorg Med Chem Lett

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1P9	Abcam K-562 NMT2 KO	Cancer cell line	Female
CVCL_D2KV	Abcam Raji NMT2 KO	Cancer cell line	Male
CVCL_TA84	HAP1 NMT2 (-)	Cancer cell line	Male
CVCL_WQ12	Abcam Jurkat NMT2 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.